Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to share the latest issue of touchREVIEWS in Ophthalmology, showcasing a diverse range of articles that highlight the innovation, interdisciplinary collaboration and continued advances driving progress in eye care today. We begin this issue with an important and under-explored topic, as Fatma et al. present an investigative review examining the potential association […]

Search Results

Showing Results for AMD

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to share the latest issue of touchREVIEWS in Ophthalmology, showcasing a diverse range of articles that highlight the innovation, interdisciplinary collaboration and continued advances driving progress in eye care today. We begin this issue with an important ...

18 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Watch a retina specialist discuss newly available treatments for AMD and DMO

Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov ...

Mark CompleteCompleted
BookmarkBookmarked

The FDA has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME). Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME while requiring fewer treatments than standard-of-care eye injections.

Mark CompleteCompleted
BookmarkBookmarked

Outlook Therapeutics has announced the 12-week efficacy and safety results from the NORSE EIGHT clinical trial evaluating ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD).1 The findings were presented at the Hawaiian Eye and Retina 2025 Meeting.

Mark CompleteCompleted
BookmarkBookmarked

4D Molecular Therapeutics, a clinical-stage genetic medicines company, has announced promising topline interim results from Part 1 of the SPECTRA clinical trial evaluating 4D-150, a novel treatment for diabetic macular edema (DME).

Mark CompleteCompleted
BookmarkBookmarked

As we eagerly await the innovations and breakthroughs that 2025 promises ophthalmlology, we reached out to some of our esteemed editorial board members to share their insights.

Mark CompleteCompleted
BookmarkBookmarked

The American Academy of Ophthalmology (AAO) 2024 meeting in Chicago showcased many advancements in retinal research that show promise for the future.

Mark CompleteCompleted
BookmarkBookmarked

We have seen plenty of innovation in ophthalmology, with researchers and clinicians making significant strides in how eye conditions are treated and managed. From improving drug delivery methods to harnessing the potential of gene and stem cell therapies, 2024 has been a year of promising progress across multiple areas. As we edge closer to 2025, we are eager to see what advancements will further improve vision and eye care. To envision what lies ahead, we turn to our expert editorial board to share their insights on the developments shaping the future of ophthalmology:

Mark CompleteCompleted
BookmarkBookmarked

The EURETINA 2024 Congress, held in Barcelona from September 19-22, brought together leading experts in ophthalmology to share the latest research and innovative treatments for retinal diseases. Among the highlights were several late-breaking abstracts that showcased promising advances in therapeutics for conditions such as retinopathy of prematurity (ROP), diabetic retinopathy (DR) and  age-related macular degeneration (AMD). These studies not only demonstrated the efficacy and safety of novel treatment options but also addressed critical unmet needs in reducing patient burden and improving long-term outcomes.

Mark CompleteCompleted
BookmarkBookmarked

A recent study published in Ophthalmology demonstrates the effectiveness of oral antioxidant and lutein/zeaxanthin supplements in slowing the progression of geographic atrophy (GA) associated with age-related macular degeneration (AMD).

Mark CompleteCompleted
BookmarkBookmarked

We are pleased to present the latest edition of touchREVIEWS in Ophthalmology. In this issue, we offer a series of engaging editorials, in-depth review articles and insightful original research highlighting some of the latest breakthroughs, innovations and practical insights in ...

Mark CompleteCompleted
BookmarkBookmarked

Age-related macular degeneration (AMD) is a chronic deterioration and dysfunction of the outer retinal tissue and Bruch’s membrane (BrM). It is the leading cause of vision loss in people older than 60 years and is estimated to affect 288 million people ...

Mark CompleteCompleted
BookmarkBookmarked

Contrast sensitivity (CS), which is an important element of functional vision, helps in differentiating an object from its background. CS affects several aspects of vision, such as acuity, dark adaptation, visual field, motion detection and pattern recognition.1 A decline in ...

Mark CompleteCompleted
BookmarkBookmarked

Neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME) are two leading causes of visual impairment and blindness in the USA.1,2 Faricimab is the first bispecific antibody approved by the US Food and Drug Administration in ophthalmology and was ...

Mark CompleteCompleted
BookmarkBookmarked

Age-related macular degeneration (AMD) is one of the main causes of irreversible vision loss in ageing populations worldwide.1 In 2019, the US recorded 1.49 million people aged 40 years or older with late-stage AMD, reflecting a crude prevalence rate of 0.94%.2 Geographic atrophy (GA), ...

Mark CompleteCompleted
BookmarkBookmarked
Luke G Qin, Venkatkrish M Kasetty, Diego Espinosa-Heidmann

Retinal pharmacotherapy encompasses various drug delivery routes that offer potential avenues for effective treatment (Figure 1). Among these, intravitreal injections have emerged as the predominant method employed in clinical practice.1 They have established themselves as the primary approach for administering anti-vascular ...

Mark CompleteCompleted
BookmarkBookmarked

Age-related macular degeneration (AMD) is a progressive eye condition that affects millions of people worldwide and poses a significant threat to vision in individuals over the age of 50.1 Of the two types of AMD, wet AMD, which is characterized by ...

Load More...
Close Popup